Oral immunotherapy with grass pollen in enterosoluble capsules. A prospective study of the clinical and immunological response.
In a prospective study spanning 2 years, 60 patients with grass pollen allergy were treated with either a low dose oral, a high dose oral or a subcutaneous hyposensitization regime. No significant improvement was seen in the orally treated patients whereas those on the subcutaneous hyposensitization regime demonstrated a decreased specific cutaneous reactivity, a rise in specific IgG antibodies and a reduction in symptoms. This study suggests that oral hyposensitization, even with enterosoluble grass pollen capsules, is ineffective.
Urbanek
R
R
Universitäts-Kinderklinik, Freiburg, Federal Republic of Germany.
Bürgelin
K H
KH
Kahle
S
S
Kuhn
W
W
Wahn
U
U
D000284:Administration, Oral; D000293:Adolescent; D002214:Capsules; D002648:Child; D003233:Conjunctivitis, Allergic / Q000628:therapy*; D003692:Delayed-Action Preparations; D003888:Desensitization, Immunologic; D005069:Evaluation Studies as Topic; D005260:Female; D006636:Histamine Release / Q000276:immunology; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007167:Immunotherapy / Q000379:methods*; D007279:Injections, Subcutaneous; D007408:Intestinal Absorption; D008297:Male; D006109:Poaceae / Q000276:immunology; D011058:Pollen / Q000276:immunology*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index
D002214:Capsules; D003692:Delayed-Action Preparations; D007074:Immunoglobulin G; D007073:Immunoglobulin E